Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.
Journal
Deutsches Arzteblatt international
ISSN: 1866-0452
Titre abrégé: Dtsch Arztebl Int
Pays: Germany
ID NLM: 101475967
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
received:
18
12
2019
revised:
18
12
2019
accepted:
27
05
2020
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
23
2
2021
Statut:
ppublish
Résumé
The incidence of cancer is increasing worldwide. The role of comorbidities in this development is debated. The aim of this study was to investigate the significance of non-alcoholic fatty liver disease (NAFLD) for the incidence of cancer of various kinds in Germany. Between 2000 and 2015, data on 31 587 patients with established NAFLD were collected for analysis. A control group (n = 31 587) assembled for comparison was matched for sex, age, treating physician, and Charlson Comorbidity Index (CCI). By 10 years after the index date, 15.3% of patients with NAFLD and 13.4% of patients in the control group had been diagnosed with cancer (p <0.001). Patients with NAFLD exhibited significantly higher rates of male genital cancers (HR 1.26; 95% confidence interval [1.06; 1.5]; p = 0.008), skin cancer (HR 1.22 [1.07; 1.38]; p = 0.002) and breast cancer (HR 1.2 [1.01; 1.43]; p = 0.036). In this analysis, the rate of hepatocellular carcinoma did not differ between patients with NAFLD and patients without NAFLD (0.19% vs. 0.12%; p = 0.204). NAFLD slightly increases the risk of breast cancer in women, genital cancer in men, and skin cancer irrespective of sex. Thus, NAFLD can be considered a marker of increased cancer risk.
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of cancer is increasing worldwide. The role of comorbidities in this development is debated. The aim of this study was to investigate the significance of non-alcoholic fatty liver disease (NAFLD) for the incidence of cancer of various kinds in Germany.
METHODS
METHODS
Between 2000 and 2015, data on 31 587 patients with established NAFLD were collected for analysis. A control group (n = 31 587) assembled for comparison was matched for sex, age, treating physician, and Charlson Comorbidity Index (CCI).
RESULTS
RESULTS
By 10 years after the index date, 15.3% of patients with NAFLD and 13.4% of patients in the control group had been diagnosed with cancer (p <0.001). Patients with NAFLD exhibited significantly higher rates of male genital cancers (HR 1.26; 95% confidence interval [1.06; 1.5]; p = 0.008), skin cancer (HR 1.22 [1.07; 1.38]; p = 0.002) and breast cancer (HR 1.2 [1.01; 1.43]; p = 0.036). In this analysis, the rate of hepatocellular carcinoma did not differ between patients with NAFLD and patients without NAFLD (0.19% vs. 0.12%; p = 0.204).
CONCLUSION
CONCLUSIONS
NAFLD slightly increases the risk of breast cancer in women, genital cancer in men, and skin cancer irrespective of sex. Thus, NAFLD can be considered a marker of increased cancer risk.
Identifiants
pubmed: 33559592
pii: arztebl.2020.0719
doi: 10.3238/arztebl.2020.0719
pmc: PMC7871444
doi:
pii:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
719-724Commentaires et corrections
Type : CommentIn
Références
Clin Gastroenterol Hepatol. 2019 Mar;17(4):748-755.e3
pubmed: 29908364
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
J Hepatol. 2019 Dec;71(6):1229-1236
pubmed: 31470068
BMC Med Res Methodol. 2019 Jul 8;19(1):142
pubmed: 31286896
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Int J Clin Pharmacol Ther. 2018 Oct;56(10):459-466
pubmed: 30168417
J Clin Transl Hepatol. 2017 Sep 28;5(3):193-196
pubmed: 28936399
Int J Mol Sci. 2016 May 12;17(5):
pubmed: 27187365
Gastroenterology. 2020 May;158(7):1929-1947.e6
pubmed: 32068022
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):786-94
pubmed: 23703499
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Dig Dis Sci. 2020 Jul;65(7):2112-2119
pubmed: 31797186
J Hepatol. 2017 Nov 02;:
pubmed: 29150142
World J Hepatol. 2015 Aug 28;7(18):2155-61
pubmed: 26328027
Hepatology. 2019 Jun;69(6):2672-2682
pubmed: 30179269
Diabetologia. 2018 Oct;61(10):2140-2154
pubmed: 30027404
BMC Cancer. 2017 Oct 25;17(1):703
pubmed: 29070034
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Aliment Pharmacol Ther. 2018 Nov;48(10):1109-1116
pubmed: 30288767
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156